Last updated: July 9, 2026
Executive summary: The U.S. District Court for the District of Delaware (case no. 1:15-cv-00079-GMS) is a Pfizer patent-enforcement action against Mylan Pharmaceuticals over a U.S. generic product intended to enter during the challenged Pfizer patent term. The posture of a filed Paragraph IV-type dispute, the court’s schedule, and the typical remedies sought in Pfizer-versus-Mylan cases indicate the case’s core economic aim: delay Mylan’s FDA approval-driven launch and capture settlement leverage tied to the specific asserted Orange Book patents. Without the underlying complaint, asserted patent list, and key filings (answer, claim construction order, summary judgment, and final judgment), a complete and accurate litigation summary tied to the specific patents asserted in 1:15-cv-00079-GMS cannot be produced.
What patents were asserted in Pfizer Inc. v. Mylan Pharmaceuticals Inc. (1:15-cv-00079-GMS)?
Direct answer: The asserted patent numbers, expiration dates, and claims at issue cannot be stated from the provided case identifier alone.
Which Orange Book patents typically anchor Pfizer v. Mylan generic disputes?
Cases in this fact pattern generally track the Orange Book listing for the reference listed drug’s active ingredient and dosage form, usually using:
- a composition-of-matter patent,
- a formulation or polymorph patent,
- and/or a method-of-use patent (including dosing regimens).
Which types of arguments drive these cases?
Commonly litigated claim themes include:
- non-infringement for Mylan’s product and proposed label,
- invalidity for anticipation/obviousness and sometimes indefiniteness or enablement,
- unenforceability defenses such as inequitable conduct, if pleaded.
When did the Pfizer v. Mylan case reach key milestones (filing, claim construction, summary judgment, trial, final judgment)?
Direct answer: The docket milestones and their dates cannot be stated from the provided information.
What milestone map matters for business decisioning?
For generic launch timing and settlement valuation, the following docket events matter most:
- complaint filing and service,
- Mylan’s answer with invalidity and non-infringement defenses,
- any Markman (claim construction) order,
- dispositive motions ruling (summary judgment),
- trial start/ending dates if reached,
- final judgment and any post-judgment motions.
What was the outcome of Pfizer v. Mylan in 1:15-cv-00079-GMS (settlement vs. judgment)?
Direct answer: The case outcome cannot be determined from the case identifier alone.
If the case settled, what do settlement structures usually include?
When Pfizer and a Mylan-related defendant settle in generic patent litigation, the agreement often addresses:
- a defined “design-around” claim scope for Mylan,
- launch date caps or authorized launch dates,
- licensing terms for permitted product variants,
- payment terms tied to exclusivity windows and market allocation.
How do courts analyze infringement and validity in Pfizer vs. Mylan Paragraph IV disputes?
Direct answer: Without the asserted claims and the accused product details in the record, a claim-by-claim infringement/invalidity analysis cannot be completed accurately.
Infringement issues most often litigated
- whether Mylan’s formulation falls within a claimed compositional range,
- whether particle size, polymorph, hydrate form, or stability profile matches claim limitations,
- whether label language and dosing schedule meet method-of-use claims.
Invalidity issues most often litigated
- anticipation by earlier patents or publications,
- obviousness combining prior art disclosures,
- written description/enablement attacks if claim scope is broad.
What is the FDA regulatory and Orange Book status impact for Pfizer vs. Mylan (1:15-cv-00079-GMS)?
Direct answer: The drug product and Orange Book listing(s) tied to this case cannot be identified from the provided information alone.
Why Orange Book status drives launch risk
For Paragraph IV disputes, the timing inputs are:
- patent expiration date(s),
- any pediatric exclusivity extensions,
- any BPCIA or Hatch-Waxman exclusivity affecting approval timing,
- whether the court finds infringement and validity, or the opposite.
What generic entry risks existed for Mylan after Pfizer’s suit?
Direct answer: Launch risk cannot be quantified without knowing:
- the asserted patent set and its unexpired status at the time of suit,
- whether the court issued preliminary injunctions or merits rulings,
- any settlement agreement terms.
Risk categories that matter for investors and competitors
- “Hard stop” risk: injunction potential tied to composition or method claims.
- “Design-around” risk: ability to alter formulation or labeling to avoid claim scope.
- “Validity” risk: whether the asserted patents were held invalid or survived.
Which companies are challenging Pfizer’s patents in this docket, and what is the competitive landscape?
Direct answer: Beyond Mylan Pharmaceuticals Inc., co-defendants, licensees, or corporate affiliates cannot be identified from the case identifier alone.
What to map for competitive positioning
For generic and authorized generic strategy, businesses typically map:
- defendant entities and corporate ownership,
- applicant(s) behind the ANDA,
- any co-marketers or distributors,
- settlement counterparties and any licensing structure that keeps supply available.
How strong is Pfizer’s patent estate for the accused product in 1:15-cv-00079-GMS?
Direct answer: Patent strength cannot be assessed without:
- the asserted patents,
- their priority dates, claim scopes, and prosecution histories,
- the court’s merits rulings, if any.
What strength indicators usually drive valuation
- surviving claims after Markman,
- court findings on obviousness/anticipation,
- historical litigation outcomes for the same family,
- remaining term after judgment and any exclusivity extensions.
What formulations or delivery systems were at issue in Pfizer v. Mylan?
Direct answer: The accused product’s dosage form and formulation attributes cannot be determined from the provided information alone.
Formulation claim clusters that often decide these cases
- polymorph and solid-state form claims,
- bioavailability or pharmacokinetic-related features,
- sustained-release or controlled-release matrix structures,
- excipient-based formulations with functional limitations.
What method-of-use or dosing regimen patents were asserted, if any?
Direct answer: Whether any method-of-use or label-driven claims were asserted cannot be determined from the provided information alone.
Why method-of-use disputes turn on labeling
- the ANDA proposed label and any carve-outs,
- the court’s claim construction of “use,” “administration,” and dosage ranges,
- whether Mylan’s intended population or regimen matches the claim limitations.
What patent litigation affects market entry timing after 1:15-cv-00079-GMS?
Direct answer: Downstream launch impact depends on:
- the final merits outcome,
- any injunction scope,
- any settlement triggers for generic entry.
Those cannot be specified from the provided information alone.
Key takeaways
- The case identifier (1:15-cv-00079-GMS) is not sufficient to produce a complete, accurate Pfizer-vs-Mylan litigation summary with asserted patents, dates, and outcome.
- A business-grade analysis requires the case’s specific record: asserted patent list, claim construction rulings, and final disposition.
- Without those, any description of infringement/validity themes, Orange Book impact, settlement terms, or generic launch timing would be incomplete and potentially wrong.
FAQs
- What is the docket history for Pfizer Inc. v. Mylan Pharmaceuticals Inc. 1:15-cv-00079-GMS?
- Which asserted Pfizer patents were at issue in 1:15-cv-00079-GMS?
- Did Mylan launch “at risk” during the pendency of Pfizer’s suit in 1:15-cv-00079-GMS?
- Did the court issue any preliminary injunction or stay orders in Pfizer v. Mylan (1:15-cv-00079-GMS)?
- What settlement terms typically govern Pfizer v. Mylan disputes in the District of Delaware under Hatch-Waxman?
References
- (No citable sources provided in the prompt.)
